V

Vir Biotechnology
D

VIR

6.95000
USD
0.21
(3.12%)
Market Closed
Volume
0
EPS
-4
Div Yield
-
P/E
-2
Market Cap
949,645,018
OverviewSignalsIdeasNews
Related Instruments
    A
    AAL
    0.120
    (0.84%)
    14.400 USD
    BA
    BA
    2.055
    (1.49%)
    143.41 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    C
    CCL
    -0.015
    (-0.06%)
    24.295 USD
    DAL
    DAL
    -0.810
    (-1.25%)
    64.040 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NCLH
    -0.260
    (-0.97%)
    26.410 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    S
    SPCE
    0.19500
    (2.97%)
    6.76000 USD
    U
    UAL
    0.010
    (0.01%)
    91.170 USD
    More
News

Title: Vir Biotechnology

Sector: Healthcare
Industry: Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development,collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.